Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse

Overview

The purpose of this study is to assess the abuse liability of 4 times (8 tablets) the usual recommended dose of Acurox (oxycodone HCl 40 mg plus niacin 240 mg) versus oxycodone HCL 40 mg alone in subjects with a history of opioid abuse.

Full Title of Study: “A Phase II, Single-Center, Randomized, Double-Blind Assessment of the Abuse Liability of Acurox (Oxycodone HCl and Niacin) Tablets in Subjects With a History of Opioid Abuse”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: August 2008

Detailed Description

In the Treatment Phase, subjects randomly received oxycodone HCl 40 mg administered in combination with niacin 240 mg and oxycodone HCl 40 mg alone in crossover design. 15 subjects were randomized to receive oxycodone/niacin first followed by oxycodone with a 48 hour washout between doses. 15 subjects randomized to receive oxycodone before the oxycodone/naicin dose with a 48 hour washout between doses. The purpose of the Treatment Phase was to assess the abuse liability and abuse deterrence potential of 4 times the recommended 2-tablet dose of Acurox® Tablets 5/30 mg versus oxycodone HCl 40 mg alone (8 tablets per dose). All 30 subjects received a single dose of each study treatment. Subjects were fasted prior to dosing on all dose days.

Interventions

  • Drug: Acurox 5/30mg taken first
    • followed by oxycodone 5mg with 48 hour washout
  • Drug: Oxycodone 5mg taken first
    • followed by Acurox 5/30mg with 48 hour washout

Arms, Groups and Cohorts

  • Active Comparator: Acurox 5/30mg taken first
    • oxycodone HCl/Niacin 5/30mg tablets; 8 tablets per dose
  • Active Comparator: Oxycodone 5mg taken first
    • oxycodone HCl 5mg tablets; 8 tablets per dose

Clinical Trial Outcome Measures

Primary Measures

  • Drug Like/Dislike Effect at 30 Minutes Post Dose (E 30 Min)
    • Time Frame: Effects assessed at 0.5 hours after dosing.
    • “Do you dislike or like the drug effect you are feeling now?” This question was rated on a 1 to 29 point VAS scale that was anchored in the center with “neither like nor dislike” (14), on the left with “dislike an awful lot” (1), and on the right with “like an awful lot” (29).

Participating in This Clinical Trial

Inclusion Criteria

  • Subject is male or female between 18 and 55 years of age – Subject meets DSM-IV Criteria for the Diagnosis of Opioid Substance Abuse and subject is unlikely to experience an idiosyncratic reaction or respiratory depression after ingesting 40 mg of oxycodone – Body weight is not more than 20% above or below ideal body weight – Subject agrees to abstain from any Rx or OTC drugs (except as authorized by the Investigator) or alcohol – Subject is in generally good health – Subject is reliable, willing, cooperative, able to communicate effectively, and has a minimum of a 6th grade reading level – Subject has an acceptable score on the MMSE for cognitive impairment – For women of child-bearing potential: woman is not pregnant and not nursing, and is practicing an acceptable method of birth control Exclusion Criteria:

  • Subject has a disease that may endanger the subject or the validity of the data – Subject is currently physically dependent on opiates or alcohol – Subject was exposed to any investigational drug within 30 days prior to the inpatient phase – Subject has a history of hypersensitivity to any drug, or a known allergy to any component of the study drug formulation – Subject has a positive urine drug screen for a non-opiate drug – Subject has a predisposing condition that may place the subject at risk for receiving niacin or oxycodone, or confound the study analyses – Subject ingested niacin at doses higher than SDI within 14 days prior to the inpatient phase – Subject has an abnormal bleeding tendency

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Acura Pharmaceuticals Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Donald R Jasinski, MD, Principal Investigator, Johns Hopkins Medical Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.